JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Efficacy evaluation of tyrosine kinase inhibitors for advanced non-small cell lung cancer patients with leptomeningeal metastasis

  • 0The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Journal of Thoracic Disease +

|

June 18, 2025

|

June 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Targeted therapy shows promise for non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM). Concurrent local therapy significantly improved progression-free and overall survival in these challenging NSCLC patients.

Area Of Science

  • Oncology
  • Medical Research
  • Clinical Trials

Background

  • Leptomeningeal metastasis (LM) is a rare but serious complication of non-small cell lung cancer (NSCLC).
  • Standardized treatment protocols for NSCLC with LM are lacking.
  • This study evaluates targeted therapy's efficacy and safety in NSCLC patients with LM.

Purpose Of The Study

  • To assess the effectiveness of targeted therapy in non-small cell lung cancer patients with leptomeningeal metastasis.
  • To provide data for improved treatment strategies for this patient group.
  • To analyze factors influencing progression-free survival in NSCLC with LM.

Main Methods

  • Retrospective analysis of 193 non-small cell lung cancer patients with leptomeningeal metastasis.
  • Patients received targeted therapy, with some also receiving concurrent leptomeningeal local therapy (chemotherapy or radiotherapy).
  • Diagnosis confirmed via cerebrospinal fluid cytology, MRI, and clinical symptoms.

Main Results

  • Median progression-free survival (mPFS) was 6.9 months; median overall survival (mOS) was 15.0 months.
  • Concurrent local leptomeningeal therapy significantly improved mPFS (11.4 vs. 6.5 months) and mOS (18.1 vs. 13.6 months).
  • Performance status, treatment lines, angiogenesis inhibitors, and local therapy were independent factors influencing PFS.

Conclusions

  • Targeted therapies offer encouraging outcomes for NSCLC patients with LM.
  • Concurrent local leptomeningeal therapy enhances survival benefits in this population.
  • Further research is warranted to optimize treatment strategies for NSCLC with LM.

Keywords: